Back to results
US 12,758,553 B2Granted
Use of poziotinib for the treatment of cancers with NRG1 fusions
AssigneeBoard of Regents, The University of Texas System
InventorsJohn Heymach, Jacqulyne Robichaux
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of selecting cancer patients for treatment with poziotinib as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with poziotinib alone or in combination with HER2/HER3 targeting antibodies.
Claims7
A method of treating a patient having a cancer, the method comprising administering to the patient a therapeutically effective amount of poziotinib, and a HER2/HER3 targeting antibody wherein the cancer has an NRG1 fusion.
Dependencies are inferred from the claim text.